國立虎尾科技大學 |

Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law/ by Daria Kim.
Author:	Kim, Daria.
Description:	XVIII, 300 p. 5 illus.online resource. :
Contained By:	Springer Nature eBook
Subject:	Mass media. -
Online resource:	https://doi.org/10.1007/978-3-030-86778-2
ISBN:	9783030867782

Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law
Kim, Daria.

Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law[electronic resource] /by Daria Kim. - 1st ed. 2021. - XVIII, 300 p. 5 illus.online resource. - Munich Studies on Innovation and Competition,162199-7470 ;. - Munich Studies on Innovation and Competition,3.

PART ONE: Setting the Scene -- Introduction -- The Context and the Problem in Focus -- Secondary Analysis of Clinical Trial Data - A Primer -- PART TWO: Analysis de lege lata,- Legal Sources of Control over and Access to Clinical Trial Data under the EU Applicable Framework -- Implications of IPD Disclosure for Statutory Innovation Incentives PART THREE: Analysis de lege ferenda -- Defining the Intervention Logic of Access-To-Data Measures - A Problem Analysis -- Access to Clinical Trial Data as a Case on R&D Externalities - A Theoretical Framework -- IPD as a Research Resource - Exclusively Controlled or Readily Accessible? -- Evaluating Legislative Options -- Final Conclusions and the Outlook.

This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors’ control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised.

ISBN: 9783030867782

Standard No.: 10.1007/978-3-030-86778-2doiSubjects--Topical Terms:

556421
Mass media.

LC Class. No.: K4240-4343

Dewey Class. No.: 343.099

Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law
LDR:03655nam a22004095i 4500 001 1056318
003 DE-He213
005 20211019132831.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030867782 $9 978-3-030-86778-2
024 7 $a 10.1007/978-3-030-86778-2 $2 doi
035 $a 978-3-030-86778-2
050 4 $a K4240-4343
072 7 $a LNJ $2 bicssc
072 7 $a LAW000000 $2 bisacsh
072 7 $a LNJ $2 thema
082 0 4 $a 343.099 $2 23
100 1 $a Kim, Daria. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1361646
245 1 0 $a Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law $h [electronic resource] / $c by Daria Kim.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a XVIII, 300 p. 5 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Munich Studies on Innovation and Competition, $x 2199-7470 ; $v 16
505 0 $a PART ONE: Setting the Scene -- Introduction -- The Context and the Problem in Focus -- Secondary Analysis of Clinical Trial Data - A Primer -- PART TWO: Analysis de lege lata,- Legal Sources of Control over and Access to Clinical Trial Data under the EU Applicable Framework -- Implications of IPD Disclosure for Statutory Innovation Incentives PART THREE: Analysis de lege ferenda -- Defining the Intervention Logic of Access-To-Data Measures - A Problem Analysis -- Access to Clinical Trial Data as a Case on R&D Externalities - A Theoretical Framework -- IPD as a Research Resource - Exclusively Controlled or Readily Accessible? -- Evaluating Legislative Options -- Final Conclusions and the Outlook.
520 $a This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors’ control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised.
650 0 $a Mass media. $3 556421
650 0 $a Law. $3 671705
650 0 $a Medical laws and legislation. $3 567375
650 0 $a Law—Europe. $3 1254279
650 0 $a Medicine. $3 644133
650 0 $a Statistics . $3 1253516
650 1 4 $a IT Law, Media Law, Intellectual Property. $3 1209939
650 2 4 $a Medical Law. $3 671732
650 2 4 $a European Law. $3 883672
650 2 4 $a Biomedicine, general. $3 1253757
650 2 4 $a Statistics, general. $3 671463
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030867775
776 0 8 $i Printed edition: $z 9783030867799
776 0 8 $i Printed edition: $z 9783030867805
830 0 $a Munich Studies on Innovation and Competition, $x 2199-7462 ; $v 3 $3 1261210
856 4 0 $u https://doi.org/10.1007/978-3-030-86778-2
912 $a ZDB-2-LCR
912 $a ZDB-2-SXLC
950 $a Law and Criminology (SpringerNature-41177)
950 $a Law and Criminology (R0) (SpringerNature-43727)